148 related articles for article (PubMed ID: 25634459)
1. [Efficacy of omalizumab in patients with severe asthma using the asthma health questionnaire and asthma control test].
Saji J; Arai M; Yamamoto T; Mineshita M; Miyazawa T
Arerugi; 2014 Dec; 63(10):1338-47. PubMed ID: 25634459
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long-term omalizumab therapy in patients with severe asthma.
Saji J; Yamamoto T; Arai M; Mineshita M; Miyazawa T
Respir Investig; 2017 Mar; 55(2):114-120. PubMed ID: 28274526
[TBL] [Abstract][Full Text] [Related]
3. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
[TBL] [Abstract][Full Text] [Related]
5. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
7. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effect of omalizumab on 10 patients with severe persistent asthma].
Kanemitsu Y; Kita H; Fuseya Y; Tanimura K; Katayama Y; Nisihara Y
Arerugi; 2010 Aug; 59(8):965-73. PubMed ID: 20820138
[TBL] [Abstract][Full Text] [Related]
9. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
[TBL] [Abstract][Full Text] [Related]
10. Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients.
Kwong KY; Jones CA
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):288-93. PubMed ID: 17042132
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
13. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
Rottem M
J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
[TBL] [Abstract][Full Text] [Related]
15. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
[TBL] [Abstract][Full Text] [Related]
16. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
17. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
19. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
20. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
